阿戈美拉汀治疗抑郁症及其对患者性功能的影响

Effects of agomelatine on depression syndrome and sexual function in depression patients

目的:观察阿戈美拉汀治疗抑郁症的疗效和安全性以及对性功能的影响。方法:将112例符合ICD-10抑郁发作诊断标准的抑郁症患者随机分成阿戈美拉汀组(n=58)和米氮平组(n=54),阿戈美拉汀组接受阿戈美拉汀治疗,米氮平组接受米氮平治疗,治疗持续8周,基线及治疗第1、2、4、8周末同时用汉密尔顿抑郁量表(HAMD)评定患者的抑郁状况,同时用亚利桑那性体验量表(ASEX)评定患者的性功能,用副反应量表(TESS)评定治疗中出现的不良反应。结果:治疗8周末阿戈美拉汀组和米氮平组的HAMD评分分别为6.9±3.7、7.8±3.4,均较治疗前显著下降,但是两组没有统计学差异(t=1.337,P=0.184)。治疗前阿戈美拉汀组和米氮平组男性的ASEX评分分别为13.5±3.3、13.0±3.1(t=0.825,P=0.411);女性分别为12.8±3.5、13.1±2.8(t=0.179,P=0.859),均没有统计学差异。治疗8周末阿戈美拉汀组男性、女性ASEX评分分别为10.8±2.5、10.5±2.4,较治疗前显著下降;米氮平组男性、女性ASEX评分分别为18.2±4.5、19.1±4.1,较治疗前显著升高,两组男性、女性研究对象间ASEX评分存在统计学差异(P<0.05)。治疗8周末两组性功能障碍例数分别为8例(13.8%)和22例(40.7%),两组存在统计学差异(χ2=4.35,P<0.05)。结论:阿戈美拉汀治疗抑郁症安全有效,同时对抑郁症患者的性功能有一定的改善作用。

AIM： To observe the efficacy and safety of agomelatine in the treatment of depression and its effects on sexual function. METHODS ： 112 depression patients were treated with agomelatine （n=58） and mitzapine （ n = 54 ） randomly. The trial lasted 8 weeks. Hamilton Depression scales （HAMD） were applied to evaluate the depression status on the baseline and 1st, 2ed ,4th, 8th week after the treatment respectively. Arizona sexual experiences scale （ASEX） were applied to evaluate the sexual function at the same time points. RE- SULTS：There were no obvious difference in HAMD between the two groups after the treatment （6.9±3.7 vs 7.8±3.4） （t = 1.337,P =0. 184）, which both declined significantly compared with the base- line. There were no obvious difference in ASEX in male patients between the two groups at baseline （13.5±3.3 vs 13.0±3.1） （t =0.825, P = 0. 411 ）, and there were also no obvious difference in female patients（12.8 ±3.5 vs 13.1 ＋2.8） （t = 0. 179,P =0. 859） . The ASEX of male and female patients in the agomelatine group were 10.8±2.5, 10.5±2.4 after 8 weeks＇ treatment which declined significantly than that at baseline, while the ASEX of male and female patients in the mitzapine group were 18.2±4.5,19.1±4.1 after 8 weeks＇treatment which increased significantly than that at baseline. The eases who had troubles in sexual function after the treatment were 8 （ 13.8% ） vs 22 （40.7%）, which has significant difference （ X2 = 4.35, P 〈 0.05 ）. CONCLUSION ： Agomelatine demonstrated to be effective and safe in the treatment of depression, and can improve patients＇sexual function.